The Systemic Aspergillosis drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Aspergillosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Aspergillosis and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Systemic Aspergillosis by six companies/universities/institutes. The top development phase for Systemic Aspergillosis is preclinical with five drugs in that stage. The Systemic Aspergillosis pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Systemic Aspergillosis pipeline products market are: Pulmonomy, Pulmatrix and Novabiotics.
The key targets in the Systemic Aspergillosis pipeline products market include Lanosterol 14 Alpha Demethylase, Ergosterol, and Cell Membrane.
The key mechanisms of action in the Systemic Aspergillosis pipeline product include Lanosterol 14 Alpha Demethylase Inhibitor with two drugs in Phase II. The Systemic Aspergillosis pipeline products include three routes of administration with the top ROA being Inhalational and two key molecule types in the Systemic Aspergillosis pipeline products market including Small Molecule, and Synthetic Peptide.
Systemic Aspergillosis overview
Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause hemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness.
For a complete picture of Systemic Aspergillosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
